First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma

Prof Burnett speaks at a conference session at ESMO 2018 in Munich about results from KEYNOTE-048, a phase 3 study of first-line pembrolizumab R/M HNSCC.
For more on these results watch her interview with ecancer.